The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Oct 2018 13:58

RNS Number : 5611C
GlaxoSmithKline PLC
01 October 2018
 

GlaxoSmithKline plc

 

Total Voting Rights and Capital

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 30 September 2018 consisted of 5,375,085,545 shares of 25 pence each ('Ordinary Shares'), of which 414,605,950 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,960,479,595. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

 

V A Whyte

Company Secretary

 

1 October 2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUGGMAUUPRGPG
Date   Source Headline
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults
11th Dec 20237:00 amRNSJemperli plus chemotherapy EU authorisation
4th Dec 20233:02 pmRNSGSK publishes provisional 2024 dividend dates
1st Dec 20233:00 pmRNSTotal Voting Rights
30th Nov 20239:00 amRNSBlock Listing Application
29th Nov 20233:23 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSGSK announces positive DREAMM-7 headline results
21st Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 20233:00 pmRNSBlock listing Interim Review
13th Nov 20233:30 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSGSK receives positive CHMP opinion for momelotinib
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSJemperli trial meets overall survival endpoint
26th Oct 20237:00 amRNSNMPA approves Vocabria+Rekambys in China
25th Oct 20233:30 pmRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSNew data for Arexvy, GSK’s RSV vaccine
20th Oct 20233:30 pmRNSDirector/PDMR Shareholding
18th Oct 20233:30 pmRNSDirector/PDMR Shareholding
17th Oct 20233:30 pmRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSJemperli plus chemotherapy positive CHMP opinion
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
12th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSZantac (ranitidine) litigation
10th Oct 202311:00 amRNSHolding(s) in Company
9th Oct 20237:00 amRNSGSK and Zhifei announce vaccine partnership
6th Oct 20237:00 amRNSGSK completes sale of shares in Haleon plc
5th Oct 20234:46 pmRNSGSK announces intention to sell shares in Haleon
2nd Oct 20233:00 pmRNSTotal Voting Rights
27th Sep 20233:00 pmRNSDirectorate Change
25th Sep 20237:00 amRNSGSK RSV vaccine for older adults approved in Japan
21st Sep 20233:30 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSApretude for PrEP receives EMA approval
18th Sep 20237:00 amRNSFDA approves Ojjaara (momelotinib)
13th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20237:00 amRNSMomelotinib filing accepted in Japan
1st Sep 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.